Two cardiometabolic events have been observed: Lilly announced topline results from the ACHIEVE-2 and ACHIEVE-5 studies of orforglipron in T2DM (view press release); and Abbott hosted its Q3 ’25 earnings call (press release; infographic). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Skye Bioscience, Amgen, Abbott, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic events has been observed from Abbott, Novartis, Biomed Industries, and Bristol Myers Squibb/Pfizer. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Pfizer, Novartis, Regeneron Pharmaceuticals, Abbott, and Sequel Med Tech/Senseonics. Below, FENIX provides highlights and insights for the respective news items.
Abbott hosted its Q1’25 earnings call (press release; infographic). Of note, there was minimal discussion of Abbott’s CGM business in prepared remarks and no questions from analysts during Q&A. Abbott’s CEO Rob Ford specifically stated, “I found it interesting we did not get a single Libre question, so you guys are very concerned on tariffs and macro…” Below, FENIX provides brief highlights and insights from the call.
A series of diabetes-related news items have been observed: a CT.gov record for Novo’s Ph3 QW insulin icodec T1DM trial (ONWARDS 6) has been observed; Dexcom announced Health Canada has authorize G6 for upper arm wear; Dario announced a virtual care initiative with MediOrbis for telehealth and remote patient monitoring; Abbott hosted its Q1 ’21 earnings call; and J&J hosted its Q1 ’21 earnings call. Below, FENIX provides highlights and insights for the respective news items.
A series of diabetes-related news items have been observed: Abbott hosted its Q4 and FY ’20 earnings call; Abbott recently published an article on its website titled “FreeStyle Libre 2 Puts NBA Legend Ray Allen at Ease;” the Apple Watch Series 7 and the Samsung Galaxy Watch4 are both reportedly going to feature glucose monitoring; and DarioHealth announced its acquisition of Upright Technologies, a digital musculoskeletal company. Below, FENIX provides highlights and insights for the respective news items.
Two diabetes-related news items have been observed: Abbott hosted its Q3 ’20 earnings call (press release) and Chugai licensed its antibody engineering technology to Novo Nordisk (press release). Below, FENIX provides highlights from the respective news items as well as insight into how Novo may leverage Chugai’s antibody technology.
Abbott announced it has received CE Mark for the Libre 3 CGM system. Unlike the Libre 1 and 2 CGM systems which require users to scan the sensor to receive their glucose readings, Libre 3 is a true real-time CGM. Additionally, Abbott has updated the Libre form factor with Libre 3 being approximately the size of two stacked US pennies. According to the press release, Abbott is planning for an EU launch “in the coming months” with no update on a potential US timeline. Below, FENIX provides thoughts on the new Libre 3 CGM features as well as potential implications to Dexcom, Medtronic, Senseonics, and other CGM manufacturers.
Abbott announced plans to launch the novel “Libre Sense Glucose Sport Biosensor” (view website), which is intended to provide glucose readings and actionable insights to athletes with and without diabetes. Libre Sense has already received CE Mark, and Abbott said the product will be launched “in the coming weeks” to eight European countries via Abbott’s non-exclusive partnership with Phil Southerland’s Supersapiens (view Supersapiens website). Below, FENIX provides a brief overview of the Libre Sense Glucose Sport Biosensor and implications to the overall glucose-sensing market.